DiaMedica Therapeutics (DMAC) Current Assets (2017 - 2026)

DiaMedica Therapeutics' Current Assets history runs 10 years deep, the most recent figure standing at $52.4 million for Q1 2026.

• On a quarterly basis, Current Assets rose 39.93% year-over-year to $52.4 million in Q1 2026; TTM through Mar 2026 was $52.4 million, a 39.93% increase from a year earlier, with the FY2025 full-year figure at $60.6 million, up 35.91% from the prior year.
• Current Assets declined to $52.4 million in Q1 2026 per DMAC's latest filing, from $60.6 million in the prior quarter.
• Across five years, Current Assets topped out at $60.6 million in Q4 2025 and bottomed at $29.7 million in Q1 2023.
• The 5-year median for Current Assets is $44.6 million (2024), against an average of $44.7 million.
• Across the five-year window, Current Assets surged 81.11% in 2022 and slumped 43.51% in 2025, its largest moves.
• Year by year, Current Assets stood at $33.8 million in 2022, then soared by 58.64% to $53.7 million in 2023, then slipped by 16.89% to $44.6 million in 2024, then soared by 35.91% to $60.6 million in 2025, then retreated by 13.63% to $52.4 million in 2026.
• Per Business Quant, the three latest DMAC Current Assets figures stand at $52.4 million (Q1 2026), $60.6 million (Q4 2025), and $56.2 million (Q3 2025).